Results 111 to 120 of about 24,341 (292)

How atypical can Atypical Hemolytic Uremic Syndrome be?

Clinical Case Reports, 2014
Key Clinical MessageA 24‐year‐old man with diarrhea found to have acute renal failure with microangiopathic hemolytic anemia (MAHA). A diagnosis of hemolytic uraemic syndrome (HUS) was made. He was initiated on plasma exchange and hemodialysis. On day 6, he was started on eculizumab. His renal functions progressively improved.
Nigam Sonu, Parnham Alan, Srinivasa Vinay, Thomas Sajan   +3 more
openaire   +3 more sources

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

Clinical Pharmacology: Advances and Applications, 2011
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj  

Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]

, 2012
Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L., Barbot, J., Costa, T., Faria, M., Mota, C., Rocha, L.   +5 more
core  

Calcineurin Inhibitor Associated Nephrotoxicity in Kidney Transplantation—A Transplant Nephrologist's Perspective

Acta Physiologica, Volume 241, Issue 5, May 2025.
ABSTRACT Aim Calcineurin inhibitors (CNIs) have revolutionized transplant medicine, improving allograft survival but posing challenges like calcineurin inhibitor‐induced nephrotoxicity (CNT). Acute CNT, often dose‐dependent, leads to vasoconstriction and acute kidney injury, with treatment focusing on CNI exposure reduction.
Carla M. Hansen, Sebastian Bachmann, Mingzhen Su, Klemens Budde, Mira Choi   +4 more
wiley   +1 more source

Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease—2025 Update

Nephrology, Volume 30, Issue S2, Page 3-56, July 2025.
Adrian Liew, Sunita Bavanandan, Chuan‐Ming Hao, Soo Kun Lim, Narayan Prasad, Manisha Sahay, Paweena Susantitaphong, Veena Roberts, Eranga Wijewickrama, Muh Geot Wong, Sydney C. W. Tang   +10 more
wiley   +1 more source

Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. [PDF]

, 2014
The presence of circulating autoantibodies, primarily to complement factor H antibodies (CFH-Abs) in plasma characterizes the autoimmune form of atypical hemolytic uremic syndrome (aHUS).
Giner, T., Hofer, J., Józsi, Mihály
core   +1 more source

Inhibition of Alternative and Terminal Complement Pathway Components Modulate the Immune Response Against Bacteria and Fungi in Whole Blood

Scandinavian Journal of Immunology, Volume 101, Issue 5, May 2025.
Complement inhibition (factor D, C3, C5, or C5aR1) blunts inflammation induced by Escherichia coli or Aspergillus fumigatus conidia in lepirudin‐treated whole blood. Inhibition decreases inflammatory markers, reduces anaphylatoxin receptor expression, and lowers cytokine production and phagocytic activity. Created in https://BioRender.com.
Leon Cyranka, Ida Mariegaard, Beatrice Fageräng, Laura Pérez‐Alós, Verena Harpf, Tom Eirik Mollnes, Peter Garred, Anne Rosbjerg   +7 more
wiley   +1 more source

Current treatment of atypical hemolytic uremic syndrome

Intractable & Rare Diseases Research, 2014
Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.).
Bernard S. Kaplan, Lawrence Copelovitch, Joann M. Spinale, Rebecca L. Ruebner   +3 more
openaire   +4 more sources

SUCCESSFUL TREATMENT FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME IN A PUERPERA

Общая реаниматология, 2016
Objective: to show the problems of differential diagnosis and treatment of atypical hemolytic-uremic syndrome in a 23-year-old patient.Results. Eculizumab (Soliris), (Alexon Pharmaceuticals Inc., USA) that is a glycosylated humanized monoclonal antibody ...
O. N. Ulitkina, Zh. S. Filippovskaya, E. I. Prokopenko, A. M. Ovezov, V. V. Likhvantsev   +4 more
doaj   +1 more source

Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome [PDF]

, 2010
Thrombotic microangiopathies (TMAs) are pathological conditions characterized by generalized microvascular occlusion by platelet thrombi, thrombocytopenia, and microangiopathic hemolytic anemia.
Mastroianni Kirsztajn, Gianna, Polito, Maria Goretti   +1 more
core   +2 more sources